摘要
目的探讨托法替布联合醋酸泼尼松对间质性肺疾病的应用效果及对动脉血气指标、肺功能及肺泡灌洗液中人Ⅱ型肺泡细胞表面抗原(Human TypeⅡAlveolar Cell Surface Antigen,KL-6)、人肺表面活性物质相关蛋白A(Human Pulmonary Surfactant Associated Protein A,SP-A)水平的影响。方法前瞻性随机选取2021年1月—2023年7月南平市第一医院收治的100例间质性肺疾病患者作为研究对象,根据治疗方法不同分为两组,各50例。所有患者均进行常规对症治疗,对照组采取醋酸泼尼松治疗,观察组采取托法替布联合醋酸泼尼松治疗,对比两组疗效、血气指标、肺功能及肺泡灌洗液中KL-6、SP-A水平。结果观察组总有效率为96.00%,高于对照组的80.00%,差异有统计学意义(χ^(2)=6.061,P<0.05)。治疗后,观察组血氧分压高于对照组,动脉血二氧化碳分压低于对照组,差异有统计学意义(P均<0.05)。治疗后,观察组第1秒用力呼气容积、用力肺活量及第1秒用力呼气容积/用力肺活量高于对照组,差异有统计学意义(P均<0.05)。治疗后,观察组肺泡灌洗液中KL-6、SP-A水平低于对照组,差异有统计学意义(P均<0.05)。结论托法替布联合醋酸泼尼松对间质性肺疾病疗效显著,可改善患者动脉血气指标,提升肺功能,降低肺泡灌洗液中KL-6、SP-A表达水平。
Objective To investigate the effect of Tofacitinib combined with prednisone acetate on interstitial lung disease and the effects on arterial blood gas index,lung function,human type II alveolar cell surface antigen(KL-6)and human pulmonary surfactant associated protein A(SP-A)in alveolar lavage fluid.Methods A total of 100 patients with interstitial lung disease admitted to the First Hospital of Nanping City from January 2021 to July 2023 were prospective randomly selected as study objects and divided into two groups with 50 cases each according to different treatment methods.All patients received conventional symptomatic treatment,the control group was treated with prednisone acetate,and the observation group was treated with tofaciib combined with prednisone acetate.The efficacy,blood gas indexes,lung function and the levels of KL-6 and SPA in alveolar lavage fluid were compared between the two groups.Results The total effective rate of the observation group was 96.00%,which was higher than that of the control group(80.00%),the difference was statistically significant(χ^(2)=6.061,P<0.05).After treatment,the blood oxygen partial pressure of the observation group was higher than that of the control group,and the arterial blood carbon dioxide fraction was lower than that of the control group,and the differences were statistically significant(both P<0.05).After treatment,forced expiratory volume in the first second,forced vital capacity and forced expiratory volume in the first second/forced vital capacity in the observation group were higher than those in the control group,and the differences were statistically significant(all P<0.05).After treatment,the levels of KL-6 and SP-A in alveolar lavage fluid in observation group were lower than those in control group,and the differences were statistically significant(both P<0.05).Conclusion Tofacitinib combined with prednisone acetate has a significant effect on interstitial lung disease,which can improve arterial blood gas indexes,enhance lung function,and reduce the expression levels of KL-6 and SP-A in alveolar lavage fluid.
作者
方婷
陈坤
黄映晖
吴永煜
纪秋红
FANG Ting;CHEN Kun;HUANG Yinghui;WU Yongyu;JI Qiuhong(Department of Respiratory and Critical Care Medicine,Nanping First Hospital,Nanping,Fujian Province,353000)
出处
《中外医疗》
2024年第13期5-8,17,共5页
China & Foreign Medical Treatment
基金
福建医科大学启航基金项目(2020QH1317)。
